{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["141(23)"],"submitter":["Bhatt DL"],"pubmed_abstract":["Background
Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events.Methods
In a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse"],"journal":["Circulation"],"pagination":["1841-1854"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7314494"],"repository":["biostudies-literature"],"pubmed_title":["Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial."],"pmcid":["PMC7314494"],"pubmed_authors":["Steg PG","Branch KRH","Liang Y","Yusuf S","Lonn E","Yusoff K","Widimsky P","Commerford P","Probstfield J","Anand SS","Felix C","Avezum A","Varigos J","Ryden L","Metsarinne K","Tonkin A","Piegas L","Sharma M","Diaz R","Fox KAA","Vinereanu D","Kakkar A","Bosch J","Stoerk S","Liu L","Shestakovska O","COMPASS Steering Committee and Investigators","Lanas F","Kim J","Verhamme P","Dans A","Ertl G","Lamy A","Verma S","Pogosova N","Berkowitz SD","Cook-Bruns N","Dagenais G","Hart R","Moayyedi P","Connolly SJ","Hori M","Guzik T","Eikelboom JW","Maggioni AP","Torp-Pedersen C","Alings M","Lewis BS","Zhu J","Parkhomenko A","O'Donnell M","Lopez-Jaramillo P","Keltai K","Aboyans V","Bhatt DL","Szarek M","Keltai M"],"additional_accession":[]},"is_claimable":false,"name":"Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.","description":"Background
Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events.Methods
In a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2026-04-30T03:51:38.63Z","creation":"2020-11-07T11:33:14Z"},"accession":"S-EPMC7314494","cross_references":{"pubmed":["32223318"],"doi":["10.1161/CIRCULATIONAHA.120.046448"]}}